May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Pegaptanib (Macugen) and Ranibizumab (Lucentis) Eye Drops Inhibit Inflammatory Corneal Neovascularization
Author Affiliations & Notes
  • A. Parthasarathy
    Corneal Service, Singapore National Eye Centre, Singapore 168751, Singapore
    T.N. Shukla Eye Hospital, T.N. Shukla Eye Hospital , Jabalpur, India
  • F. Bock
    Department of Ophthalmology, Interdisciplinary Center for Clinical Research (IZKF), Friedrich-Alexander University Erlangen-Nürnberg, Germany
  • J. Onderka
    Department of Ophthalmology,, Interdisciplinary Center for Clinical Research (IZKF), Friedrich-Alexander University Erlangen, Erlangen, Germany
  • F. E. Kruse
    Department of Ophthalmology, Friedrich-Alexander University, Erlangen, Germany
  • C. Cursiefen
    Corneal Service, Interdisciplinary Center for Clinical Research (IZKF), Friedrich-Alexander University, Erlangen, Germany
  • Footnotes
    Commercial Relationships  A. Parthasarathy, None; F. Bock, None; J. Onderka, None; F.E. Kruse, None; C. Cursiefen, None.
  • Footnotes
    Support  Interdisciplinary Center for Clinical Research (IZKF) Germany, International Council of Ophthalmology, Switzerland
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3746. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Parthasarathy, F. Bock, J. Onderka, F. E. Kruse, C. Cursiefen; Pegaptanib (Macugen) and Ranibizumab (Lucentis) Eye Drops Inhibit Inflammatory Corneal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3746. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To analyze the effects of topical application of ranibizumab and pegaptanib as eye drops on suture-induced inflammatory corneal neovascularization. The target of both drugs is the vascular endothelial growth factor VEGF-A. Whereas Lucentis is a Fab-Fragment of a recombinant, humanized, monoclonal anti-VEGF antibody, Macugen is an RNA-oligonucleotide (RNA-aptamer) which binds and thereby blocks specific VEGF-A.

Methods: : A mouse model of suture induced inflammatory corneal neovascularization was used to study the effects of topical application of ranibizumab (Lucentis, Novartis, Switzerland;n=10) and pegaptanib sodium (Macugen, Pfizer, Germany;n=10). Three interrupted 11-0 nylon sutures were placed intrastromally in 6 week old BALB/c mice. The study groups received topical ranibizumab (5 mg/ml) and pegaptanib (1 mg/ml) four times per day for four days. Control mice (n=10) received an equal volume of saline solution. After one week the mice were euthanized and the corneal flat mounts were stained using CD31 as panendothelial marker. Morphometry of blood vessels was performed with the image analysis software Cell^F (Olympus Soft Imaging Solutions GmbH, Münster, Germany). An unpaired t test was used to compare the groups.

Results: : Morphometry using the software mentioned provided objective and accurate results for comparison of the groups. Topical application of ranibizumab and pegaptanib inhibited the outgrowth of blood vessels significantly (ranibizumab: p<0.02; pegaptanib: p=0.01).

Keywords: cornea: basic science • neovascularization • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×